查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602214

疫苗市场：按类型、技术类型、给药途径、适应症、年龄层划分 - 2025-2030 年全球预测

Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Route of administration, Indication, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年疫苗市值为689.2亿美元，预计2024年将达到741.6亿美元，复合年增长率为7.70%，到2030年将达到1158.9亿美元。

疫苗是提供针对特定疾病的免疫力的生物製药，在预防保健中扮演重要角色。疫苗市场涉及广泛的领域，包括预防疾病的预防性疫苗和治疗疾病的治疗性疫苗。 COVID-19 大流行等全球健康挑战加剧了对疫苗的需求，增加了对 mRNA 疫苗等新疫苗技术的需求。最终用途包括医院、诊所和研究机构。一个关键的成长要素是对全球免疫计画的认识和投资的提高，并由各国政府和非政府组织进一步推动。技术进步，加上研发资金的增加，为相关人员在疫苗输送机制和稳定性方面进行创新创造了有利可图的机会。然而，严格的监管政策、不断上升的研发成本和疫苗犹豫等挑战可能会阻碍市场成长。此外，开发中国家的供应链中断和准入不平等也构成了重大限制。有前景的创新和研究领域包括个人化技术、辅助技术和无针给药系统，这些技术有可能提高疗效和患者依从性。它还表明製药公司、科技公司和公共卫生机构之间的合作可以加速突破。寻找数位健康解决方案来简化疫苗分发和追踪结果代表着开拓的潜力。儘管存在竞争格局，但不断变化的治疗需求和全球公共卫生安全的需求正在培养特定市场的扩张。总体而言，疫苗市场准备应对可用性和可负担性的挑战，同时利用个人化免疫疗法和区块链等新机会来提高供应链透明度的技术创新，预计将持续成长。

主要市场统计
基准年[2023] 689.2亿美元
预测年份 [2024] 741.6亿美元
预测年份 [2030] 1158.9亿美元
复合年增长率（%） 7.70%

市场动态：揭示快速发展的疫苗市场的关键市场洞察

供需的动态交互作用正在改变疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人们越来越认识到新兴感染疾病的爆发和疫苗接种的好处
    • 增加政府资金鼓励疫苗开发
  • 市场限制因素
    • 高开发成本和产品召回问题
  • 市场机会
    • 生技公司开发创新疫苗的投资激增
    • 透过建立公私伙伴关係改善疫苗分配
  • 市场挑战
    • 疫苗核准过程的长度和相关的疫苗副作用

波特的五力：驾驭疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对疫苗市场的影响

外部宏观环境因素对疫苗市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解疫苗市场的竞争状况

对疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵疫苗市场供应商绩效评估

FPNV定位矩阵是评估疫苗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人们越来越认识到新感染疾病的传播和疫苗接种的好处
      • 增加政府资金加速疫苗开发
    • 抑制因素
      • 开发成本上升和产品召回问题
    • 机会
      • 生技公司开发创新疫苗的投资激增
      • 公私合营的兴起改善了疫苗的分配
    • 任务
      • 漫长的疫苗核准过程和相关的疫苗副作用
  • 市场区隔分析
    • 类型：接触不同株时，多效价疫苗至关重要
    • 技术类型：快速发展和高效提高了mRNA疫苗的重要性
    • 给药途径：由于强烈的免疫反应，优选肌内（IM）和皮下（SC）途径。
    • 适应症：传播流感疫苗以预防季节性流感流行
    • 年龄层：老年人和慢性病患者需要有效接种疫苗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章疫苗市场：依类型

  • 单价疫苗
  • 多效价疫苗

第七章疫苗市场：依技术类型

  • 无效疫苗
  • 减毒活疫苗
  • 传讯RNA(mRNA) 疫苗
  • 次单元、重组、多醣体和结合疫苗
  • 类毒素疫苗
  • 病毒载体疫苗

第八章疫苗市场：依给药途径分类

  • 肌肉内和皮下
  • 口服

第九章 疫苗市场：依适应症分类

  • b型流感嗜血桿菌
  • 甲型肝炎和B型肝炎
  • 人类乳突病毒
  • 麻疹、腮腺炎、德国麻疹
  • 病菌感染感染
  • 肺炎链球菌感染
  • 脊髓灰质炎
  • 狂犬病
  • 轮状病毒
  • 带状疱疹
  • 破伤风、白喉、百日咳
  • 水痘

第10章疫苗市场：依年龄组

  • 成人
  • 小儿科

第十一章美洲疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Mankind Pharma 20 亿美元收购 Bharat Serums and Vaccines 扩大疫苗产能
    • 赛诺菲和 Novavax 合作共同商业化新的 COVID-19 疫苗并开发流感/冠状病毒联合疫苗
    • CureVac 和 MD 安德森合作开发以 mRNA 为基础的癌症疫苗，为先进癌症治疗铺路
    • Bharat Biotech 与 Bilthoven Biologicals 合作，透过提高 OPV 产量加强全球根除脊髓灰质炎工作
    • 武田製药合作改善全球登革热疫苗的可近性，瞄准高影响地区
    • Astra Zeneca收购生物技术公司 Icosavax 以加强疫苗能力
    • 印度血清研究所与 CEPI 合作，改善疫情期间全球疫苗的获取
    • GSK与智飞合作在中国独家经销带状疱疹疫苗Shingrix，旨在改善公众健康和疫苗可及性
    • 杨森和赛诺菲合作开发疫苗计划，以满足未满足的医疗需求
    • 全球努力加强大流行防范，为 Genova 的自放大 mRNA 疫苗（针对 X 型感染疾病）提供资金
    • 巴伐利亚北欧公司在美国推出 Mpox 疫苗，促进预防保健和市场创新
  • 战略分析和建议
    • Astra Zeneca
    • 辉瑞公司
    • GlaxoSmithKline Plc
    • 默克公司
    • 赛诺菲公司

公司名单

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Emergent BioSolutions Inc.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 68.92 billion in 2023, expected to reach USD 74.16 billion in 2024, and is projected to grow at a CAGR of 7.70%, to USD 115.89 billion by 2030.

Vaccines are biological preparations that provide immunity against specific diseases and are critical in preventive healthcare. The vaccine market encompasses a broad spectrum including prophylactic vaccines for disease prevention and therapeutic vaccines for disease treatment. The necessity of vaccines has been underscored by global health challenges such as the COVID-19 pandemic, increasing the demand for novel vaccine technologies like mRNA vaccines. Applications extend beyond infectious diseases to areas such as cancer, allergies, and autoimmune disorders, while end-use sectors include hospitals, clinics, and research institutes. A significant growth factor is the increased awareness and investments in immunization programs worldwide, further propelled by government and non-governmental organizations. Technological advancements, coupled with expanding research and development funding, present lucrative opportunities for stakeholders to innovate in vaccine delivery mechanisms and stability. However, challenges such as stringent regulatory policies, high R&D costs, and vaccine hesitancy might impede market growth. Moreover, supply chain disruptions and inequitable access in developing countries represent substantial limitations. Promising areas for innovation and research include personalized vaccines, adjuvant technology, and needle-free delivery systems, which could enhance effectiveness and patient compliance. Insights indicate that collaboration between pharmaceutical companies, tech firms, and public health organizations can accelerate breakthroughs. Exploring digital health solutions for enhancing vaccine distribution efficiency and outcome tracking presents untapped potential. Despite the competitive landscape, the market's inherent expansion is nurtured by evolving therapeutic needs and the imperative for global public health security. Overall, the vaccine market holds promise for continuous growth, contingent upon addressing challenges of accessibility and affordability, while leveraging technological innovations to tap into emerging opportunities like personalized immunotherapy and blockchain for supply chain transparency.

KEY MARKET STATISTICS
Base Year [2023] USD 68.92 billion
Estimated Year [2024] USD 74.16 billion
Forecast Year [2030] USD 115.89 billion
CAGR (%) 7.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccines Market

The Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
    • Increased government funding encouraging vaccine development
  • Market Restraints
    • High development costs and Issues over product recalls
  • Market Opportunities
    • Surge in investments by biotech companies for innovative vaccine development
    • Emerging collaborations between public and private sectors improve vaccine distribution
  • Market Challenges
    • Lengthy vaccine approval processes and associated side impacts of vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccines Market

A detailed market share analysis in the Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccines Market

A strategic analysis of the Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on Technology Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
  • Based on Route of administration, market is studied across Intramuscular & Subcutaneous and Oral.
  • Based on Indication, market is studied across Haemophilus Influenzae Type b, Hepatitis A & Hepatitis B, Human Papillomavirus, Measles, Mumps, & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rabies, Rotavirus, Shingles/Herpes Zoster, Tetanus, Diphtheria, & Pertussis, and Varicella.
  • Based on Age Group, market is studied across Adults and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
      • 5.1.1.2. Increased government funding encouraging vaccine development
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and Issues over product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in investments by biotech companies for innovative vaccine development
      • 5.1.3.2. Emerging collaborations between public and private sectors improve vaccine distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Lengthy vaccine approval processes and associated side impacts of vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Critical need for Multivalent vaccines in case of exposure to various strains
    • 5.2.2. Technology Type: Growing significance of mRNA vaccines due to their rapid development and high efficacy
    • 5.2.3. Route of Administration: High preferences for intramuscular (IM) and subcutaneous (SC) routes owing to their strong immune response
    • 5.2.4. Indication: Widespread adoption of influenza vaccines for preventing seasonal flu outbreaks
    • 5.2.5. Age Group: Need for effective vaccination for the elderly and individuals with chronic health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccines
  • 7.3. Live-Attenuated Vaccines
  • 7.4. Messenger RNA (mRNA) Vaccines
  • 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 7.6. Toxoid Vaccines
  • 7.7. Viral Vector Vaccines

8. Vaccines Market, by Route of administration

  • 8.1. Introduction
  • 8.2. Intramuscular & Subcutaneous
  • 8.3. Oral

9. Vaccines Market, by Indication

  • 9.1. Introduction
  • 9.2. Haemophilus Influenzae Type b
  • 9.3. Hepatitis A & Hepatitis B
  • 9.4. Human Papillomavirus
  • 9.5. Measles, Mumps, & Rubella
  • 9.6. Meningococcal Disease
  • 9.7. Pneumococcal Disease
  • 9.8. Polio
  • 9.9. Rabies
  • 9.10. Rotavirus
  • 9.11. Shingles/Herpes Zoster
  • 9.12. Tetanus, Diphtheria, & Pertussis
  • 9.13. Varicella

10. Vaccines Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Pediatric

11. Americas Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mankind Pharma to Acquire Bharat Serums and Vaccines in USD 2 Billion Deal, Expanding Vaccine Production Capabilities
    • 14.3.2. Sanofi and Novavax Partner to Co-Commercialize New COVID-19 Vaccine and Develop Flu-COVID Combo Shot
    • 14.3.3. CureVac and MD Anderson Team Up to Develop mRNA-Based Cancer Vaccines, Paving the Way for Advanced Cancer Treatments
    • 14.3.4. Bharat Biotech and Bilthoven Biologicals Unite to Boost Global Polio Eradication Efforts with Enhanced OPV Production
    • 14.3.5. Takeda Forms Partnership to Boost Global Access to Dengue Vaccine, Targeting Hard-Hit Regions
    • 14.3.6. AstraZeneca Bolsters Vaccine Capabilities by Acquiring Biotechnology Firm Icosavax
    • 14.3.7. Serum Institute of India Partners with CEPI to Boost Global Vaccine Accessibility During Epidemics
    • 14.3.8. GSK Partners with Zhifei to Exclusively Distribute Shingles Vaccine Shingrix in China, Aiming to Enhance Public Health and Vaccine Access
    • 14.3.9. Janssen and Sanofi Join Forces to Develop Vaccine Program to Address Unmet Medical Needs
    • 14.3.10. Global Initiative Boosts Pandemic Preparedness with Funding for Gennova's Self-Amplifying mRNA Vaccine against Disease X
    • 14.3.11. Bavarian Nordic Launches Mpox Vaccine in the U.S., Boosting Preventive Healthcare and Market Innovation
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. AstraZeneca PLC
    • 14.4.2. Pfizer Inc.
    • 14.4.3. GlaxoSmithKline PLC
    • 14.4.4. Merck & Co., Inc.
    • 14.4.5. Sanofi S.A.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech Ltd.
  • 6. Biological E. Limited
  • 7. BioNTech SE
  • 8. Blue Lake Biotechnology
  • 9. Capricor Therapeutics, Inc.
  • 10. Chongqing Zhifei Biological Products Co., Ltd.
  • 11. CSL Limited
  • 12. CureVac N.V.
  • 13. Daiichi Sankyo Company, Limited.
  • 14. Emergent BioSolutions Inc.
  • 15. Gennova Biopharmaceuticals Limited
  • 16. GlaxoSmithKline PLC
  • 17. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 18. Incepta Pharmaceuticals Ltd.
  • 19. Inovio Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Merck & Co., Inc.
  • 22. Moderna, Inc.
  • 23. Novavax, Inc.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Serum Institute of India Pvt. Ltd.
  • 27. Sinovac Biotech Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. VBI Vaccines Inc.
  • 30. Versatope Therapeutics
  • 31. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY HAEMOPHILUS INFLUENZAE TYPE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY MEASLES, MUMPS, & RUBELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY SHINGLES/HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY TETANUS, DIPHTHERIA, & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 246. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023